Besponsa Post Marketing Surveillance Study

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. Number of AEs were classified as per action taken for AEs (withdrawn \[temporarily or permanently or delayed\]; dose reduced; dose increased; dose not changed; unknown, and not applicable) in this outcome measure. Not applicable per protocol referred to situations if participant died or if the treatment was completed prior to the reaction/event or if drug was not administered.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE and Overall Number of Units Analyzed signifies evaluable number of AEs.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. Number of AEs were classified as per SAEs category (resulted in death; is life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect and is an important medical event) in this outcome measure. One SAE could have more than 1 outcome/characteristic and have been counted in more than one category.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any SAE and Overall Number of Units Analyzed signifies evaluable number of SAEs.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. AEs' severity was graded using common terminology criteria for AEs (CTCAE) version 4.0; grade 1= mild AE; grade 2= moderate AE; grade 3= severe AE; grade 4= life-threatening AE and grade 5= death.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE and Overall Number of Units Analyzed signifies evaluable number of AEs.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. Number of AEs were classified as per their outcomes (recovered, recovered with sequelae, recovering, not recovered, and unknown) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE and Overall Number of Units Analyzed signifies evaluable number of AEs.

AE: any untoward medical occurrence in participant administered medicinal product. Number of AEs per causality of AE to study drug (certain, probable/likely, possible, unlikely, conditional/unclassified, and not-assessable/unclassifiable) were reported. Certain: couldn't be explained by other drugs, had clinically reasonable reaction on cessation of drug and pharmacological/phenomenological reaction to drug re-administration. Probable/likely: couldn't be explained by other drugs, had clinically reasonable reaction on drug cessation. Possible: could also be explained by other drugs, lacked information/unclear information on drug discontinuation. Unlikely: not likely to have causal relationship from drug administration, could also be explained by other drugs. Conditional/unclassified: needed more data to make appropriate assessment/additional of data being reviewed. Not-assessable: lacked sufficient information/conflicting information hampering accurate causality assessment.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE and Overall Number of Units Analyzed signifies evaluable number of AEs.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily have a causal relationship with the product treatment or usage. Number of AEs were classified as per other causality of AE to the study drug (disease under the study, other disease, concomitant treatment drug or non-drug, and others) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE and Overall Number of Units Analyzed signifies number of AEs evaluable for this outcome measure.

An ADR was any untoward medical occurrence attributed to a medicinal product in a participant who had received that product. In this outcome measure, number of elderly participants (\>=65 years) with ADRs at baseline were reported.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who were \>=65 years with any AEs.

An ADR was any untoward medical occurrence attributed to medicinal product in participant who had received that product. SADR was an ADR that resulted in any of the following: death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect; or was an important medical event.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. AEs included both SAEs and all non-SAEs. An SAE was any untoward medical occurrence in a participant administered a medicinal or nutritional product at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or was an important medical event.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. Number of participants with AEs were classified according to their baseline demographic characteristics of age (less than \[\<\] 65 years and more than or equal to \[\>=\] 65 years) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily have a causal relationship with the product treatment or usage. Number of participants with AEs were classified according to their baseline demographic characteristics of allergic history (yes or no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. Number of participants with AEs were classified according to their baseline demographic characteristics of diagnosis (Philadelphia \[+\] B-cell Acute Lymphoblastic Leukemia \[ALL\], Philadelphia \[-\] B-cell ALL, and unknown) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. Refractory Disease: failure to achieve complete response (CR) at the end of induction. Relapsed disease: Reappearance of blasts in the blood or bone marrow (\>5%) or in any extramedullary site after a CR. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, absolute neutrophil count (ANC) \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. Number of participants with AEs were classified according to their baseline demographic characteristics of disease status (refractory, first relapsed, second relapsed and third or more relapsed) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily have a causal relationship with the product treatment or usage. Number of participants with AEs were classified according to their baseline demographic characteristics of hepatic disorder status (yes or no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily have a causal relationship with the product treatment or usage. Number of participants with AEs were classified according to their baseline demographic characteristics of previous hematopoietic cell transplant status (yes, no, and unknown) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily have a causal relationship with the product treatment or usage. Number of participants with AEs were classified according to their baseline demographic characteristics of previous systemic therapy status (yes, no, and unknown) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily have a causal relationship with the product treatment or usage. Number of participants with AEs were classified according to their baseline demographic characteristics of renal disorder status (yes or no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. Number of participants with AEs were classified according to their baseline demographic characteristics of sex (female and male) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily have a causal relationship with the product treatment or usage. VOD also known as SOS is a potentially life-threatening condition in which the small veins in the liver are blocked. This obstruction impairs blood flow through the liver and can lead to liver damage and failure. Number of participants with AEs were classified according to their baseline demographic characteristics of VOD/SOS (yes or no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily have a causal relationship with the product treatment or usage. Number of participants with AEs were classified according to the use of concomitant medications (yes and no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) up to the end of study (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure who had any AE.

An ADR was any untoward medical occurrence attributed to medicinal product in participant who had received that product. SADR was an ADR that resulted in any of the following: death; was life-threatening; required inpatient hospitalization/prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect; or was important medical event. In this outcome measure, number of participants with unexpected ADRs and SADRs are reported. An ADR was considered expected if the reported event and its specificity or severity were consistent with as pre-specified in the protocol, other than these all ADRs were unexpected.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once.

An AE was any untoward medical occurrence in a participant administered a medicinal product. The event need not necessarily had a causal relationship with the product treatment or usage. An SAE was any untoward medical occurrence in a participant administered a medicinal or nutritional product at any dose that: resulted in death; is life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or was an important medical event. An AE was considered expected if the reported event and its specificity or severity were consistent with as pre-specified in the protocol, other than these all AEs were unexpected.

Time frame: From first dose of study intervention (Day 1) up to 28 days post last dose of study intervention (maximum up to 311 days)

Population: The safety analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated with safety-related outcome measures at least once.

BOR was defined as the best response recorded from the start of treatment until disease progression (PD) or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. Ineffectiveness was defined as BOR of refractory disease, PD, or relapsed disease. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. Refractory Disease: failure to achieve CR at the end of induction. Relapsed disease: Reappearance of blasts in the blood or bone marrow (\>5%) or in any extramedullary site after a CR.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures.

BOR was defined as the best response recorded from the start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. The number of participants with effective BOR were classified according to their baseline demographic characteristic of sex (female and male) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR was defined as the best response recorded from the start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. The number of participants with effective BOR were classified according to their baseline demographic characteristic of age (\<65 years and \>=65 years) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR: best response recorded from start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. The number of participants with effective BOR were classified according to their baseline demographic characteristic of allergic history (yes and no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR was defined as the best response recorded from the start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. The number of participants with effective BOR were classified according to their baseline demographic characteristic of diagnosis (Philadelphia \[+\] B-cell ALL, Philadelphia \[-\] B-cell ALL and unknown) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR: best response recorded from start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. Refractory Disease: failure to achieve CR at the end of induction. Relapsed disease: Reappearance of blasts in the blood or bone marrow (\>5%) or in any extramedullary site after a CR. The number of participants with effective BOR were classified according to their baseline demographic characteristic of disease status (refractory, first relapsed, second relapsed and third or more relapsed) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR: best response recorded from start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. The number of participants with effective BOR were classified according to their baseline demographic characteristic of hepatic disorder (yes and no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR: best response recorded from start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \>1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. The number of participants with effective BOR were classified according to their baseline demographic characteristic of previous hematopoietic cell transplant (yes, no and unknown) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR: best response recorded from start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. The number of participants with effective BOR were classified according to their baseline demographic characteristic of previous systemic therapy (yes, no and unknown) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR: best response recorded from start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. The number of participants with effective BOR were classified according to their baseline demographic characteristic of renal disorder (yes and no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR: best response recorded from start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. VOD also known as SOS is a potentially life-threatening condition in which the small veins in the liver are blocked. This obstruction impairs blood flow through the liver and can lead to liver damage and failure. The number of participants with effective BOR were classified according to their baseline demographic characteristic of VOD/SOS (yes and no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.

BOR: best response recorded from start of treatment until PD or recurrence. Effectiveness was defined as a BOR of CR or CR with incomplete hematologic recovery. PD: Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. CR: No circulating blasts or extramedullary disease, trilineage hematopoiesis and \< 5% blasts, ANC \> 1000/microliter, platelets \>100000/microliter and no recurrence for 4 weeks. CR with incomplete hematologic recovery: met all criteria for CR except platelet count and/or ANC. The number of participants with effective BOR were classified according to usage of concomitant medication (yes and no) in this outcome measure.

Time frame: From first dose of study intervention (Day 1) until disease progression or recurrence (maximum up to 311 days)

Population: The effectiveness analysis set included participants who have been administered Inotuzumab Ozogamicin at least once and evaluated based upon effectiveness outcome measures. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure with effective BOR.